eli lilly retatrutide study infiltrates anti-obesity market as Phase III trial for begins Eli Lilly retatrutide Phase 3

Consider these factors: Benefits to discuss: Blood sugar control, weight loss, potential cardiovascular benefits, and possible cancer-protective effects

At weeks 20 and 24, clinical response, defined as 20% reduction in weekly PS volume, was achieved in 65.7% (p=0.0243) of patients who received glepaglutide twice weekly, 45.7% who received glepaglutide once weekly, and 38.9% who received placebo

You may not notice dramatic changes yet, but subtle shifts are beginning

They found that GLP-1 users experienced chronic cough approximately 29% more often than patients taking alternatives such as DPP-4 inhibitors, SGLT2 inhibitors, and sulfonylureas